Background and purpose: Orbital non-Hodgkin's lymphomas (NHL) have traditio
nally been treated with radiation. Forty-eight patients presenting with orb
ital NHL were treated with radiation and were evaluated for local control,
overall survival, cause-specific survival, and complications.
Materials and methods: Forty-five patients had low-grade and 3 patients had
intermediate-grade histologic findings. Orbit-only disease occurred in 22
patients, the conjunctiva in 16, both in five, and lacrimal gland only in f
ive. Patient age ranged from 35 to 94 years (median, 68). Ann Arbor stages
were cIEA (34), cIIEA (six), cIILEA (two), and cIVEA (six). Radiation doses
ranged between 15 and 53.8 Gy (median, 27.5 Gy).
Results: Follow-up ranged from 0.14 to 18.23 years (median, 5.35). Median o
verall survival and cause-specific survival were 6.5 and 15.5 years, respec
tively. Patients with clinical stage I or II disease had significantly bett
er overall and cause-specific survival than patients with stage III or IV d
isease. Ten-year relapse-free survival in 41 patients with stage I or II di
sease was 66%. However, there was continued downward pressure on relapse-fr
ee survival out to 18 years. One local failure occurred. Twenty-five patien
ts sustained acute complications. There were 17 minor and four major late c
omplications. All major late complications occurred with doses more than 35
Gy.
Conclusions: Excellent local control with radiation doses ranging from 15 t
o 30 Gy is achieved. Patients with stage I or II disease have better overal
l and cause-specific survival than patients with stage III or IV disease. L
ate relapse occurs in sites other than the treated orbit, even in patients
with early-stage disease. Doses 35 Gy or higher result in significant late
complications and are therefore not indicated for patients with low-grade t
umors. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.